$SMSI

Smith Micro (SMSI) Q2 2026 Earnings Call Transcript

Smith Micro (SMSI) reported Q2 2026 revenue of $4.3M, down 2% YoY but up 3% sequentially. The company expects Q3 revenue of $5.0M-$5.4M, driven by new contracts and product launches. Gross margin improved to 81.3%, and operating expenses decreased significantly. The company anticipates adding resources to support pipeline growth, potentially increasing non-GAAP operating expenses by up to 6% in Q3.

Original reporting
Published Aug 22, 2026, 3:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 3:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Smith Micro (SMSI) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SMSINeutralMed
01

Why it matters

Earnings release provides fresh guidance and reveals cost‑reduction progress, offering a basis for short‑term trading decisions.

02

Market read

Micro‑cap earnings with modest guidance; relevance mainly to traders focused on small‑cap tech and margin trends.

03

What to watch

Potential upside from pending multi‑year contract extension and new SafePath SDK/API offerings.

Relevance 6/10Novelty 7/10Timing: post‑earnings Q2 2026 release

Background

Smith Micro reported Q2 2026 results, noting a slight revenue decline YoY but strong margin improvement and a reverse stock split.

Company-level read

Ticker impact

$SMSINeutralMedium confidence
Context

Q2 2026 earnings call disclosed revenue of $4.3M, gross margin 81.3%, and guidance for Q3 revenue $5.0M-$5.4M.

Expected impact

Potential modest upside if market values improved margins and Q3 guidance; downside risk if revenue miss concerns persist.

Evidence & confidence

Micro‑cap with low absolute numbers; improved margins may attract value buyers, but revenue decline limits upside.

Market effects

Highlights continued demand for safety software in consumer and enterprise segments.

Limited to U.S. small‑cap tech space.

Low; company is niche with minimal global exposure.

Counterpoint

Margin expansion may be temporary; revenue decline suggests underlying demand weakness.

Key entities

  • Smith Micro

    Provider of safety and security software solutions.

  • Bethany Braund

    Speaker presenting the earnings details.

Related articles

$SMSIMed

SMITH MICRO SOFTWARE, INC. (SMSI): Results of Operations and Financial Condition

SMITH MICRO SOFTWARE, INC. (SMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_979029.htm EXHIBIT 99.1 ex_979029.htm Exhibit 99.1 IR INQUIRIES: Charles Messman Investor Relations 412-837-5300 IR@smithmicro.com Smith Micro Reports Second Quarter 2026 Financial Results PITTSBURGH, PA, August 13, 2026 – Smith Micro Software, Inc. ( Nasdaq: SMSI )

$DELLHigh

Dell added to Evercore Tactical Outperform List ahead of earnings

Evercore ISI added Dell Technologies (NYSE:DELL) to its 'tactical outperform list' ahead of earnings, citing strong AI server demand and supply constraints. The firm expects a solid quarterly beat and raised fiscal 2027 guidance, with AI servers as the main growth driver. Street estimates project $44.9B revenue and $4.89 EPS, up 51% YoY. Dell's AI backlog stands at $51.3B, with supply constraints expected to persist.

$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

$PFEHighAI 8/10

Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?

Pfizer (NYSE:PFE) reported a 1% operational revenue increase in Q2 2026 to $15.0B, with non-COVID products growing 5%. Management raised full-year guidance. Newer products like Padcev and Vyndaqel showed growth, but patent expirations pose risks. Cost savings targets were expanded to $5.7B by 2026 and $6.7B by 2029. Revenue growth was modest, and GAAP pre-tax loss was reported due to various charges.